Whales with a lot of money to spend have taken a noticeably bearish stance on Summit Therapeutics.
Looking at options history for Summit Therapeutics SMMT we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 22% of the investors opened trades with bullish expectations and 77% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $305,983 and 3, calls, for a total amount of $105,141.
Expected Price Movements
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $10.0 to $50.0 for Summit Therapeutics over the recent three months.
Volume & Open Interest Trends
In terms of liquidity and interest, the mean open interest for Summit Therapeutics options trades today is 1946.33 with a total volume of 414.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Summit Therapeutics's big money trades within a strike price range of $10.0 to $50.0 over the last 30 days.
Summit Therapeutics Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SMMT | PUT | SWEEP | BEARISH | 01/16/26 | $31.6 | $31.1 | $31.6 | $50.00 | $63.2K | 4.0K | 40 |
| SMMT | PUT | SWEEP | BEARISH | 01/16/26 | $31.6 | $31.1 | $31.6 | $50.00 | $63.2K | 4.0K | 60 |
| SMMT | PUT | SWEEP | BEARISH | 01/16/26 | $31.5 | $29.1 | $31.5 | $50.00 | $63.0K | 4.0K | 100 |
| SMMT | CALL | SWEEP | BEARISH | 09/19/25 | $4.7 | $4.5 | $4.7 | $20.00 | $51.7K | 347 | 0 |
| SMMT | PUT | TRADE | BEARISH | 01/16/26 | $31.7 | $31.1 | $31.52 | $50.00 | $47.2K | 4.0K | 5 |
About Summit Therapeutics
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
After a thorough review of the options trading surrounding Summit Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Current Position of Summit Therapeutics
- Trading volume stands at 1,464,334, with SMMT's price up by 5.33%, positioned at $19.16.
- RSI indicators show the stock to be may be approaching overbought.
- Earnings announcement expected in 32 days.
What The Experts Say On Summit Therapeutics
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $35.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * An analyst from Truist Securities has revised its rating downward to Buy, adjusting the price target to $35.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Summit Therapeutics, Benzinga Pro gives you real-time options trades alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
